<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudoporphyria</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudoporphyria</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pseudoporphyria</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Craig A Elmets, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H30223457"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pseudoporphyria is a bullous photodermatosis with the clinical and histologic features of porphyria cutanea tarda (PCT), in the absence of abnormalities in porphyrin metabolism [<a href="#rid1">1</a>]. Pseudoporphyria has been associated with medications, chronic renal failure and hemodialysis, and tanning beds. Patients typically present with skin fragility, bullae, milia, and scarring on the dorsum of the hands and other sun-exposed areas  (<a class="graphic graphic_picture graphicRef80856 graphicRef83262" href="/d/graphic/80856.html" rel="external">picture 1A-B</a>). Histologically, there is a noninflammatory subepidermal blister.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of pseudoporphyria. PCT and other types of porphyrias associated with photosensitivity are discussed separately. Other photosensitivity disorders are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7108.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H30223464"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Pseudoporphyria is a rare condition; its exact incidence is unknown. It occurs at any age and more frequently in women than in men. Pseudoporphyria has been reported in approximately 10 percent of children taking <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, a nonsteroidal anti-inflammatory drug (NSAID) routinely used in the therapy of juvenile idiopathic arthritis [<a href="#rid2">2</a>]. Among children treated with naproxen, risk factors for the development of pseudoporphyria include skin phototypes I or II  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>), blue/gray eyes, and the concurrent use of <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> [<a href="#rid2">2-4</a>]. Naproxen and other propionic acid derivative NSAIDs are also the most common cause of pseudoporphyria in adults [<a href="#rid5">5,6</a>]. Pseudoporphyria has been reported in approximately 1 to 16 percent of hemodialysis patients [<a href="#rid7">7-10</a>].</p><p class="headingAnchor" id="H30223471"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Four factors have been implicated in the etiology of pseudoporphyria: ultraviolet (UV) radiation, medications, chronic renal failure and hemodialysis, and tanning beds. </p><p class="headingAnchor" id="H182198836"><span class="h2">Ultraviolet radiation</span><span class="headingEndMark"> — </span>Although the exact pathogenetic mechanism is unknown, drug-induced pseudoporphyria is considered a photodynamic phototoxic drug reaction. In this type of reaction, the photosensitizing compound, upon absorption of the appropriate wavelength radiation, changes to an excited state and reacts with oxygen to form reactive oxygen species (ROS), such as singlet oxygen, hydrogen peroxide, or superoxide anion. ROS can damage cell components, such as nucleic acids, membranes, lipids, and proteins. Mediators of inflammation and inflammatory cells participate in tissue injury, including products of complement activation, proinflammatory cytokines, arachidonic acid metabolites, proteases, and polymorphonuclear leukocytes.</p><p class="headingAnchor" id="H21925384"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Pseudoporphyria was first identified among individuals taking the quinolone antibiotic nalidixic acid [<a href="#rid11">11-13</a>]. Subsequently, a variety of other medications have been associated with pseudoporphyria, including nonsteroidal anti-inflammatory drugs (NSAIDs), other types of antibiotics, diuretics, retinoids, and antineoplastic agents  (<a class="graphic graphic_table graphicRef83233" href="/d/graphic/83233.html" rel="external">table 2</a>) [<a href="#rid1">1,6,14-19</a>]. Tyrosine kinase inhibitors <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> and <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, used in the treatment of several cancers, and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> have also been associated with pseudoporphyria [<a href="#rid15">15,16,20-24</a>].</p><p><a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">Naproxen</a>, an NSAID derived from propionic acid, is responsible for most cases of pseudoporphyria [<a href="#rid3">3,4,25-32</a>]. Propionic acid derivative NSAIDs (eg, naproxen, <a class="drug drug_general" data-topicid="9725" href="/d/drug information/9725.html" rel="external">oxaprozin</a>, <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a>, and <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>) are more likely to cause pseudoporphyria than other classes of NSAIDs [<a href="#rid5">5,33-42</a>]. However, several nonpropionic acid NSAIDs (eg, <a class="drug drug_general" data-topicid="9357" href="/d/drug information/9357.html" rel="external">diflunisal</a>, <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, <a class="drug drug_general" data-topicid="9601" href="/d/drug information/9601.html" rel="external">mefenamic acid</a>, and <a class="drug drug_general" data-topicid="9671" href="/d/drug information/9671.html" rel="external">nabumetone</a>) have also been associated with pseudoporphyria [<a href="#rid33">33-36,42,43</a>].</p><p>It is unknown why pseudoporphyria manifests with vesicles and bullae, whereas drug-induced phototoxic reactions usually appear as exaggerated sunburns [<a href="#rid13">13,31,44</a>]. It is also unknown why pseudoporphyria usually continues for months after the drug has been discontinued. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Phototoxicity'</a>.) </p><p class="headingAnchor" id="H1008808"><span class="h2">Hemodialysis and peritoneal dialysis</span><span class="headingEndMark"> — </span>Pseudoporphyria occurs in patients with end-stage kidney disease who are receiving chronic hemodialysis or peritoneal dialysis [<a href="#rid45">45-47</a>]. In case series, 0.6 to 16 percent of patients on hemodialysis developed the disease [<a href="#rid7">7-10</a>]. Aluminum hydroxide in dialysis solutions or chemicals in polyvinyl chloride dialysis tubing are suspected to be the photosensitizing agents in these patients [<a href="#rid48">48,49</a>]. Other theories include an inability to handle oxidative stress due to reduced levels of the endogenous antioxidant glutathione [<a href="#rid50">50</a>]. Patients with end-stage kidney disease may also have elevated plasma porphyrins due to impaired excretion and decreased porphyrin clearance by hemodialysis or peritoneal dialysis [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H21925405"><span class="h2">Tanning beds and other artificial ultraviolet A sources</span><span class="headingEndMark"> — </span>Pseudoporphyria was reported in a small number of women with frequent exposure to high doses of ultraviolet A (UVA) radiation from tanning beds [<a href="#rid53">53-57</a>]. In some cases, the patients were using medications (eg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, antibiotics, or oral contraceptives) that are known inducers of pseudoporphyria. There is a case report of UV radiation from nail hardening lamps aggravating pseudoporphyria [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H30223506"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The histologic features of pseudoporphyria closely resemble those of porphyria cutanea tarda (PCT) and other types of porphyria that cause blistering. Histologic examination of a bullous lesion typically shows a noninflammatory subepidermal blister with a scant perivascular lymphocytic infiltrate  (<a class="graphic graphic_picture graphicRef83260" href="/d/graphic/83260.html" rel="external">picture 2</a>). Festooning (ie, the preservation of the dermal papillae in the floor of the lesion) may be seen [<a href="#rid1">1,44,53,59</a>]. </p><p>Cytoid or "caterpillar" bodies, which are considered a specific histopathologic finding of porphyrias, are also seen in pseudoporphyria  (<a class="graphic graphic_picture graphicRef83388" href="/d/graphic/83388.html" rel="external">picture 3</a>) [<a href="#rid59">59,60</a>]. Caterpillar bodies are segmented and elongated structures containing laminin and type IV collagen that are positioned parallel to the epidermis [<a href="#rid60">60,61</a>]. Endothelial wall thickening from periodic acid-Schiff-positive, diastase-resistant material may be seen in the upper dermal microvasculature. </p><p>Direct immunofluorescence of lesional and perilesional skin reveals changes similar to those seen in PCT. Immunoglobulin G (IgG), immunoglobulin M (IgM), C3, and fibrinogen are frequently found at the dermoepidermal junction and in the vessel walls of lesional and perilesional skin  (<a class="graphic graphic_picture graphicRef83261" href="/d/graphic/83261.html" rel="external">picture 4</a>) [<a href="#rid59">59</a>]. Deposits of immunoglobulin and complement may be seen in the dermal vasculature in a doughnut-shaped pattern [<a href="#rid59">59,62</a>]. However, the absence of immunoreactants in dermal vessels and at the basement membrane zone does not exclude the diagnosis of pseudoporphyria. </p><p>Immunofluorescent antigen mapping has been performed to determine the level of skin splitting in pseudoporphyria. Using this technique, type IV collagen, laminin, and bullous pemphigoid antigen have been observed at the base of the blister, with no characteristic cleavage level [<a href="#rid63">63</a>]. However, ultrastructural studies have shown a split in the superficial dermis, with the basal lamina, hemidesmosomes, anchoring fibrils, and collagen fibers in the roof of the blister [<a href="#rid31">31,53</a>]. </p><p class="headingAnchor" id="H30223513"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with pseudoporphyria present with bullae and vesicles typically localized to the dorsum of the hands, forearms, and face  (<a class="graphic graphic_picture graphicRef80856 graphicRef83262" href="/d/graphic/80856.html" rel="external">picture 1A-B</a>). Lesions may also occur on the lower legs and feet. Skin fragility and easy bruising after minor trauma are common complaints  (<a class="graphic graphic_picture graphicRef83391" href="/d/graphic/83391.html" rel="external">picture 5</a>) [<a href="#rid28">28,29,64</a>]. Bullae heal with scarring and milia in most patients [<a href="#rid4">4,25,31,62,65</a>]. </p><p>In contrast to porphyria cutanea tarda (PCT), hypertrichosis, hyperpigmentation, and sclerodermoid changes are rarely reported in pseudoporphyria  (<a class="graphic graphic_table graphicRef83258" href="/d/graphic/83258.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/7108.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H298933"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>In most cases, drug-induced pseudoporphyria has a protracted course. Cutaneous lesions continue to develop even after the offending drug has been discontinued. In one series of 16 patients, the symptoms resolved within six months of discontinuation of the medication in 5 patients but persisted for an average of 2.5 years after discontinuation in 11 [<a href="#rid62">62</a>]. </p><p class="headingAnchor" id="H30223520"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of pseudoporphyria is based upon the combination of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous manifestations similar to those found in porphyria cutanea tarda (PCT) (eg, skin fragility, vesicles and bullae involving sun-exposed skin, particularly the face and the dorsum of the hands)  (<a class="graphic graphic_picture graphicRef80856 graphicRef83262" href="/d/graphic/80856.html" rel="external">picture 1A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histologic finding of subepidermal blister with scant perivascular lymphocytic infiltrate  (<a class="graphic graphic_picture graphicRef83260" href="/d/graphic/83260.html" rel="external">picture 2</a>). On direct immunofluorescence, detection of IgG, IgM, C3, and fibrinogen at the dermoepidermal junction and in the vessel walls  (<a class="graphic graphic_picture graphicRef83261" href="/d/graphic/83261.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal porphyrin levels in plasma, erythrocytes, urine, and stool. (See  <a class="medical medical_review" href="/d/html/7101.html" rel="external">"Porphyrias: An overview", section on 'Diagnostic testing (blistering cutaneous porphyria suspected)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reported use of potentially phototoxic medications  (<a class="graphic graphic_table graphicRef83233" href="/d/graphic/83233.html" rel="external">table 2</a>), history of chronic renal failure and dialysis, or ultraviolet A (UVA) exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because the clinical and histologic features of pseudoporphyria closely resemble those of PCT, pseudoporphyria is often only considered after evaluation for PCT has revealed normal porphyrin levels. This is an essential diagnostic criterion of pseudoporphyria.</p><p></p><p>In some instances, it may be necessary to obtain serology for antinuclear antibodies, antitype VII collagen antibodies, and anti-Ro/SSA and anti-La/SSB antibodies to exclude bullous lupus or epidermolysis bullosa acquisita. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Phototesting is not helpful in the evaluation of patients suspected of having pseudoporphyria. Although some individuals will exhibit a reduced minimal erythema dose (MED) to UVA, neither phototesting nor photoprovocation testing has been successful in reproducing the subepidermal blisters characteristic of the disease. </p><p class="headingAnchor" id="H30223527"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of pseudoporphyria includes porphyria cutanea tarda (PCT), erythropoietic protoporphyria (EPP), other less common cutaneous porphyrias (ie, variegate porphyria, hereditary coproporphyria, congenital erythropoietic porphyria), and other bullous disorders presenting with similar clinical manifestations, including epidermolysis bullosa acquisita, bullous pemphigoid, bullous lupus erythematosus, and hydroa vacciniforme. </p><p class="headingAnchor" id="H24847950"><span class="h2">Porphyria cutanea tarda</span><span class="headingEndMark"> — </span>Porphyria cutanea tarda (PCT) is a defect of porphyrin metabolism due to an inherited or acquired deficiency of hepatic uroporphyrinogen decarboxylase (UROD) and precipitated by several cofactors, including alcohol abuse, iron overload, hepatitis C, HIV infection, drugs  (<a class="graphic graphic_table graphicRef83258" href="/d/graphic/83258.html" rel="external">table 3</a>), and end-stage kidney disease [<a href="#rid66">66,67</a>]. PCT usually presents in adulthood with blisters, bullae, increased fragility, scarring, and hyper- and hypopigmentation affecting sun-exposed areas of the body, such as the backs of the hands, forearms, face, ears, neck, and feet  (<a class="graphic graphic_picture graphicRef78547 graphicRef74528 graphicRef56810" href="/d/graphic/78547.html" rel="external">picture 6A-C</a>).</p><p>Measurement of total porphyrins in plasma, serum, or urine can differentiate PCT and the other less common cutaneous porphyrias from pseudoporphyria. However, distinguishing pseudoporphyria from PCT in the setting of end-stage kidney disease may be difficult.</p><p>In patients on hemodialysis or peritoneal dialysis, plasma porphyrins may be elevated in the absence of UROD deficiency due to impaired excretion and inefficient porphyrin clearance by the renal replacement therapy [<a href="#rid51">51,52,68</a>]. However, in these patients, the plasma porphyrin levels are lower than those seen in patients with PCT, and there is no predominance of the heptacarboxylic fraction typically seen in PCT [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/7108.html" rel="external">"Porphyria cutanea tarda and hepatoerythropoietic porphyria: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H8050207"><span class="h2">Epidermolysis bullosa acquisita</span><span class="headingEndMark"> — </span>Epidermolysis bullosa acquisita is a rare autoimmune bullous disease caused by autoantibodies against type VII collagen  (<a class="graphic graphic_picture graphicRef62505" href="/d/graphic/62505.html" rel="external">picture 7A</a>). Serous or hemorrhagic blisters are localized to areas of trauma, especially on the dorsum of the hands and feet and elbows. They heal with scarring, milia, and hyperpigmentation. On direct immunofluorescence, there is a linear deposit of IgG at the basement membrane zone. Circulating autoantibodies against collagen VII can be demonstrated by enzyme-linked immunosorbent assay (ELISA) techniques. (See  <a class="medical medical_review" href="/d/html/15299.html" rel="external">"Epidermolysis bullosa acquisita"</a>.)</p><p class="headingAnchor" id="H8050214"><span class="h2">Bullous pemphigoid</span><span class="headingEndMark"> — </span>Bullous pemphigoid is an autoimmune bullous disease occurring most commonly in older individuals. Urticarial plaques and tense bullae may occur in all body areas  (<a class="graphic graphic_picture graphicRef79112" href="/d/graphic/79112.html" rel="external">picture 8</a>). Direct immunofluorescence of perilesional skin shows IgG and C3, or C3 alone along the basement membrane zone. Circulating antibodies against the bullous pemphigoid antigen BP 180 can be detected by ELISA techniques. (See  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p class="headingAnchor" id="H2073313829"><span class="h2">Pemphigus</span><span class="headingEndMark"> — </span>Pemphigus is an autoimmune bullous disease caused by the development of autoantibodies to intercellular adhesion molecules desmoglein 1 and 3. Patients develop flaccid blisters and erosions, both on sun-exposed and sun-protected skin  (<a class="graphic graphic_picture graphicRef53425" href="/d/graphic/53425.html" rel="external">picture 9</a>). There are reports of pemphigus induced or aggravated by exposure to ultraviolet (UV) light [<a href="#rid69">69-72</a>]. Direct immunofluorescence staining showing intercellular deposition of IgG as well as the detection of circulating autoantibodies against cell surface antigens in serum are diagnostic. (See  <a class="medical medical_review" href="/d/html/83684.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of pemphigus"</a>.)</p><p class="headingAnchor" id="H8050230"><span class="h2">Bullous lupus erythematosus</span><span class="headingEndMark"> — </span>Bullous lupus erythematosus is an uncommon form of systemic lupus erythematosus caused by autoantibodies against type VII collagen [<a href="#rid73">73</a>]. Vesicles and tense bullae are most often localized to the neck and upper trunk but also may develop on unexposed skin  (<a class="graphic graphic_picture graphicRef66048" href="/d/graphic/66048.html" rel="external">picture 10</a>). Direct immunofluorescence demonstrates linear deposition of IgG, immunoglobulin A (IgA), IgM, and C3 along the dermoepidermal junction. Salt-split skin is positive for IgG, IgA, and IgM on the floor of the blister. (See  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus", section on 'Bullous cutaneous lupus erythematosus'</a>.)</p><p class="headingAnchor" id="H8050245"><span class="h2">Hydroa vacciniforme</span><span class="headingEndMark"> — </span>In children with facial blistering, hydroa vacciniforme  (<a class="graphic graphic_picture graphicRef68305 graphicRef54500" href="/d/graphic/68305.html" rel="external">picture 11A-B</a>) can mimic pseudoporphyria. Hydroa vacciniforme is a rare photodermatosis of childhood characterized by vesicular lesions on sun-exposed skin that heal leaving depressed scars. (See  <a class="medical medical_review" href="/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment", section on 'Hydroa vacciniforme'</a>.)</p><p class="headingAnchor" id="H79691651"><span class="h2">Erythropoietic protoporphyria</span><span class="headingEndMark"> — </span>Erythropoietic protoporphyria (EPP) is an autosomal recessive or pseudodominant disease of porphyrin metabolism due to ferrochelatase deficiency and characterized by painful, nonblistering photosensitivity usually manifesting in early childhood  (<a class="graphic graphic_table graphicRef57800" href="/d/graphic/57800.html" rel="external">table 4</a>) [<a href="#rid66">66,67</a>]. Soon after or even during sun exposure, patients develop a severe burning or stinging pain that may be followed by redness, swelling, and petechiae formation  (<a class="graphic graphic_picture graphicRef98729" href="/d/graphic/98729.html" rel="external">picture 12</a>). Petechiae may last several days. The face and dorsum of the hands are most commonly affected. Repeated exposures may result in shallow vacciniforme scarring, perioral furrows, and waxy skin thickening  (<a class="graphic graphic_picture graphicRef98730" href="/d/graphic/98730.html" rel="external">picture 13</a>). The diagnosis of EPP is based upon the demonstration of a markedly increased free erythrocyte protoporphyrin. (See  <a class="medical medical_review" href="/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p class="headingAnchor" id="H30223534"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Discontinuation of the offending agent and photoprotection are the most important aspects of the management of patients with pseudoporphyria. Evidence of efficacy of pharmacologic agents, such as <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, is limited to a few case reports:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinuation of the offending agent </strong>– For patients with drug-induced pseudoporphyria, discontinuation of the offending agent (if possible) is a crucial aspect of management. The resolution of the clinical manifestations is slow. Patients can expect gradual improvement with a decrease in blistering and skin fragility over a period of months to years [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinuation of tanning bed use </strong>– For patients with pseudoporphyria associated with excessive exposure to artificial ultraviolet A (UVA) sources from tanning beds, discontinuation of the practice is essential for the control of disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photoprotection </strong>– Photoprotection is essential for all patients with pseudoporphyria. Photoprotection should continue at least until resolution of symptoms. Photoprotection measures include sun avoidance, use of protective clothing (long-sleeved shirts, blouses, pants, wide-brimmed hats), and broad-spectrum sunscreens  (<a class="graphic graphic_table graphicRef73127" href="/d/graphic/73127.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a><strong> </strong>– A beneficial effect of N-acetylcysteine has been reported in a few patients with chronic renal failure and hemodialysis-associated pseudoporphyria [<a href="#rid74">74-80</a>]. N-acetylcysteine is a precursor of glutathione, an endogenous antioxidant, the levels of which are reduced in hemodialysis patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other </strong>– There is a single report of a patient with hemodialysis-associated pseudoporphyria successfully treated with oral glutathione [<a href="#rid78">78</a>]. In another single case report, hemodialysis-associated pseudoporphyria was successfully treated with oral <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> [<a href="#rid81">81</a>]. Two patients on hemodialysis responded to photoprotection and vitamin D supplementation [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H656218"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology </strong>– Pseudoporphyria is a bullous photodermatosis with the clinical and histologic features of porphyria cutanea tarda (PCT), in the absence of abnormalities in porphyrin metabolism. Pseudoporphyria has been reported in approximately 10 percent of children taking <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> for juvenile idiopathic arthritis. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Although the exact pathogenetic mechanism is unknown, pseudoporphyria is considered a photodynamic phototoxic drug reaction. It is most often caused by medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, diuretics, and antineoplastic agents  (<a class="graphic graphic_table graphicRef83233" href="/d/graphic/83233.html" rel="external">table 2</a>). (See <a class="local">'Etiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– The clinical manifestations of pseudoporphyria closely resemble those of PCT and include skin fragility, bullae, and vesicles involving sun-exposed areas of the body, such as the face and dorsum of the hands  (<a class="graphic graphic_picture graphicRef80856 graphicRef83262" href="/d/graphic/80856.html" rel="external">picture 1A-B</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of pseudoporphyria is made in a patient with clinical and histologic features of PCT; normal porphyrin levels in red blood cells, plasma, urine, and stool; and reported use of phototoxic medications, hemodialysis, or tanning beds. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– Pseudoporphyria should be differentiated from PCT  (<a class="graphic graphic_picture graphicRef78547 graphicRef74528 graphicRef56810" href="/d/graphic/78547.html" rel="external">picture 6A-C</a>), erythropoietic protoporphyria  (<a class="graphic graphic_picture graphicRef98729" href="/d/graphic/98729.html" rel="external">picture 12</a>), other less common photocutaneous porphyrias, and bullous disorders presenting with similar clinical manifestations, including epidermolysis bullosa acquisita  (<a class="graphic graphic_picture graphicRef62505 graphicRef83259" href="/d/graphic/62505.html" rel="external">picture 7A-B</a>), bullous pemphigoid  (<a class="graphic graphic_picture graphicRef79112" href="/d/graphic/79112.html" rel="external">picture 8</a>), pemphigus  (<a class="graphic graphic_picture graphicRef53425" href="/d/graphic/53425.html" rel="external">picture 9</a>), bullous lupus erythematosus  (<a class="graphic graphic_picture graphicRef66048" href="/d/graphic/66048.html" rel="external">picture 10</a>), and hydroa vacciniforme  (<a class="graphic graphic_picture graphicRef68305 graphicRef54500" href="/d/graphic/68305.html" rel="external">picture 11A-B</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Discontinuation of the offending agent and photoprotection are the most important aspects of the management of patients with pseudoporphyria. <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> may be helpful for hemodialysis-associated pseudoporphyria. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol 2001; 44:100.</a></li><li><a class="nounderline abstract_t">Schäd SG, Kraus A, Haubitz I, et al. Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis. Arthritis Res Ther 2007; 9:R10.</a></li><li><a class="nounderline abstract_t">De Silva B, Banney L, Uttley W, et al. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol 2000; 17:480.</a></li><li><a class="nounderline abstract_t">Levy ML, Barron KS, Eichenfield A, Honig PJ. Naproxen-induced pseudoporphyria: a distinctive photodermatitis. J Pediatr 1990; 117:660.</a></li><li><a class="nounderline abstract_t">LaDuca JR, Bouman PH, Gaspari AA. Nonsteroidal antiinflammatory drug-induced pseudoporphyria: a case series. J Cutan Med Surg 2002; 6:320.</a></li><li><a class="nounderline abstract_t">Beer K, Applebaum D, Nousari C. Pseudoporphyria: discussion of etiologic agents. J Drugs Dermatol 2014; 13:990.</a></li><li><a class="nounderline abstract_t">Masmoudi A, Ben Hmida M, Mseddi M, et al. [Cutaneous manifestations of chronic hemodialysis. Prospective study of 363 cases]. Presse Med 2006; 35:399.</a></li><li><a class="nounderline abstract_t">Brivet F, Drüeke T, Guillemette J, et al. Porphyria cutanea tarda-like syndrome in hemodialyzed patients. Nephron 1978; 20:258.</a></li><li><a class="nounderline abstract_t">Griffon-Euvrard S, Thivolet J, Laurent G, et al. [Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author's transl)]. Dermatologica 1977; 155:193.</a></li><li><a class="nounderline abstract_t">Attia EA, Hassan SI, Youssef NM. Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case-controlled study. Int J Dermatol 2010; 49:1024.</a></li><li><a class="nounderline abstract_t">ZELICKSON AS. PHOTOTOXIC REACTION WITH NALIDIXIC ACID. JAMA 1964; 190:556.</a></li><li><a class="nounderline abstract_t">Ramsay CA. Photosensitivity from nalidixic acid. Proc R Soc Med 1973; 66:747.</a></li><li><a class="nounderline abstract_t">Ramsay CA, Obreshkova E. Photosensitivity from nalidixic acid. Br J Dermatol 1974; 91:523.</a></li><li class="breakAll">Frank J, Poblete-Gutierrez R. Porphyria. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Mosby Elsevier, 2008. p.648.</li><li><a class="nounderline abstract_t">Sharp MT, Horn TD. Pseudoporphyria induced by voriconazole. J Am Acad Dermatol 2005; 53:341.</a></li><li><a class="nounderline abstract_t">Kwong WT, Hsu S. Pseudoporphyria associated with voriconazole. J Drugs Dermatol 2007; 6:1042.</a></li><li><a class="nounderline abstract_t">Tolland JP, McKeown PP, Corbett JR. Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed 2007; 23:29.</a></li><li><a class="nounderline abstract_t">Dolan CK, Hall MA, Blazes DL, Norwood CW. Pseudoporphyria as a result of voriconazole use: a case report. Int J Dermatol 2004; 43:768.</a></li><li><a class="nounderline abstract_t">Lenfestey A, Friedmann D, Burke WA. Metformin-induced pseudoporphyria. J Drugs Dermatol 2012; 11:1272.</a></li><li><a class="nounderline abstract_t">Berghoff AT, English JC 3rd. Imatinib mesylate-induced pseudoporphyria. J Am Acad Dermatol 2010; 63:e14.</a></li><li><a class="nounderline abstract_t">Timmer-de Mik L, Kardaun SH, Kramer MH, et al. Imatinib-induced pseudoporphyria. Clin Exp Dermatol 2009; 34:705.</a></li><li><a class="nounderline abstract_t">Mahon C, Purvis D, Laughton S, et al. Imatinib mesylate-induced pseudoporphyria in two children. Pediatr Dermatol 2014; 31:603.</a></li><li><a class="nounderline abstract_t">Pérez NO, Esturo SV, Viladomiu Edel A, et al. Pseudoporphyria induced by imatinib mesylate. Int J Dermatol 2014; 53:e143.</a></li><li><a class="nounderline abstract_t">Sanz-Motilva V, Martorell-Calatayud A, Llombart B, et al. Sunitinib-induced pseudoporphyria. J Eur Acad Dermatol Venereol 2015; 29:1848.</a></li><li><a class="nounderline abstract_t">Lang BA, Finlayson LA. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr 1994; 124:639.</a></li><li><a class="nounderline abstract_t">Girschick HJ, Hamm H, Ganser G, Huppertz HI. Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment. Scand J Rheumatol 1995; 24:108.</a></li><li><a class="nounderline abstract_t">Creemers MC, Chang A, Franssen MJ, et al. Pseudoporphyria due to naproxen. A cluster of 3 cases. Scand J Rheumatol 1995; 24:185.</a></li><li><a class="nounderline abstract_t">Burns DA. Naproxen pseudoporphyria in a patient with vitiligo. Clin Exp Dermatol 1987; 12:296.</a></li><li><a class="nounderline abstract_t">Diffey BL, Farr PM. Naproxen pseudoporphyria in a patient with vitiligo. Clin Exp Dermatol 1988; 13:207.</a></li><li><a class="nounderline abstract_t">Rivers JK, Barnetson RS. Naproxen-induced bullous photodermatitis. Med J Aust 1989; 151:167.</a></li><li><a class="nounderline abstract_t">Judd LE, Henderson DW, Hill DC. Naproxen-induced pseudoporphyria. A clinical and ultrastructural study. Arch Dermatol 1986; 122:451.</a></li><li><a class="nounderline abstract_t">Suarez SM, Cohen PR, DeLeo VA. Bullous photosensitivity to naproxen: "pseudoporphyria". Arthritis Rheum 1990; 33:903.</a></li><li><a class="nounderline abstract_t">Taylor BJ, Duffill MB. Pseudoporphyria from nonsteroidal antiinflammatory drugs. N Z Med J 1987; 100:322.</a></li><li><a class="nounderline abstract_t">Cummins R, Wagner-Weiner L, Paller A. Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis. J Rheumatol 2000; 27:2938.</a></li><li><a class="nounderline abstract_t">Cron RQ, Finkel TH. Nabumetone induced pseudoporphyria in childhood. J Rheumatol 2000; 27:1817.</a></li><li><a class="nounderline abstract_t">Checketts SR, Morgan GJ Jr. Two cases of nabumetone induced pseudoporphyria. J Rheumatol 1999; 26:2703.</a></li><li><a class="nounderline abstract_t">Meggitt SJ, Farr PM. Pseudoporphyria and propionic acid non-steroidal anti-inflammatory drugs. Br J Dermatol 1999; 141:591.</a></li><li><a class="nounderline abstract_t">Magro CM, Crowson AN. Pseudoporphyria associated with Relafen therapy. J Cutan Pathol 1999; 26:42.</a></li><li><a class="nounderline abstract_t">Krischer J, Scolari F, Kondo-Oestreicher M, et al. Pseudoporphyria induced by nabumetone. J Am Acad Dermatol 1999; 40:492.</a></li><li><a class="nounderline abstract_t">Varma S, Lanigan SW. Pseudoporphyria caused by nabumetone. Br J Dermatol 1998; 138:549.</a></li><li><a class="nounderline abstract_t">Al-Khenaizan S, Schechter JF, Sasseville D. Pseudoporphyria induced by propionic acid derivatives. J Cutan Med Surg 1999; 3:162.</a></li><li><a class="nounderline abstract_t">Antony F, Layton AM. Nabumetone-associated pseudoporphyria. Br J Dermatol 2000; 142:1067.</a></li><li><a class="nounderline abstract_t">O'Hagan AH, Irvine AD, Allen GE, Walsh M. Pseudoporphyria induced by mefenamic acid. Br J Dermatol 1998; 139:1131.</a></li><li><a class="nounderline abstract_t">Epstein JH, Tuffanelli DL, Seibert JS, Epstein WL. Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization. Arch Dermatol 1976; 112:661.</a></li><li><a class="nounderline abstract_t">Gilchrest B, Rowe JW, Mihm MC Jr. Bullous dermatosis of hemodialysis. Ann Intern Med 1975; 83:480.</a></li><li><a class="nounderline abstract_t">Harvey E, Bell CH, Paller AS, et al. Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy. J Pediatr 1992; 121:749.</a></li><li><a class="nounderline abstract_t">Glynne P, Deacon A, Goldsmith D, et al. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria? Am J Kidney Dis 1999; 34:155.</a></li><li><a class="nounderline abstract_t">Bencini PL, Montagnino G, Citterio A, et al. Cutaneous abnormalities in uremic patients. Nephron 1985; 40:316.</a></li><li><a class="nounderline abstract_t">Neergaard J, Nielsen B, Faurby V, et al. On the exudation of plasticizers from PVC haemodialysis tubings. Nephron 1975; 14:263.</a></li><li><a class="nounderline abstract_t">Schettler V, Wieland E, Methe H, et al. Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Nephrol Dial Transplant 1998; 13:2588.</a></li><li><a class="nounderline abstract_t">Anderson CD, Rossi E, Garcia-Webb P. Porphyrin studies in chronic renal failure patients on maintenance hemodialysis. Photodermatol 1987; 4:14.</a></li><li><a class="nounderline abstract_t">Fevang SA, Kroon S, Skadberg Ø. Pseudoporphyria or porphyria cutanea tarda? Diagnostic and treatment difficulties. Acta Derm Venereol 2008; 88:426.</a></li><li><a class="nounderline abstract_t">Murphy GM, Wright J, Nicholls DS, et al. Sunbed-induced pseudoporphyria. Br J Dermatol 1989; 120:555.</a></li><li><a class="nounderline abstract_t">Wilson CL, Mendelsohn SS. Identical twins with sunbed-induced pseudoporphyria. J R Soc Med 1992; 85:45.</a></li><li><a class="nounderline abstract_t">Stenberg A. Pseudoporphyria and sunbeds. Acta Derm Venereol 1990; 70:354.</a></li><li><a class="nounderline abstract_t">Thomsen K. Solarium pseudoporphyria. Photodermatol 1989; 6:61.</a></li><li><a class="nounderline abstract_t">Kochs C, Mühlenstädt E, Neumann NJ, Hanneken S. [Solarium-induced pseudoporphyria and variegate porphyria as rare differential diagnoses of porphyria cutanea tarda]. Hautarzt 2009; 60:790.</a></li><li><a class="nounderline abstract_t">Doolan BJ, Mellerio JE, Semkova K, et al. Pseudoporphyria induced by ultraviolet radiation. Australas J Dermatol 2020; 61:177.</a></li><li><a class="nounderline abstract_t">Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 1992; 19:40.</a></li><li><a class="nounderline abstract_t">Fung MA, Murphy MJ, Hoss DM, et al. The sensitivity and specificity of "caterpillar bodies" in the differential diagnosis of subepidermal blistering disorders. Am J Dermatopathol 2003; 25:287.</a></li><li><a class="nounderline abstract_t">Egbert BM, LeBoit PE, McCalmont T, et al. Caterpillar bodies: distinctive, basement membrane-containing structures in blisters of porphyria. Am J Dermatopathol 1993; 15:199.</a></li><li><a class="nounderline abstract_t">Schanbacher CF, Vanness ER, Daoud MS, et al. Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc 2001; 76:488.</a></li><li><a class="nounderline abstract_t">Dabski C, Beutner EH. Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol 1991; 25:28.</a></li><li><a class="nounderline abstract_t">Motley RJ. Pseudoporphyria due to dyazide in a patient with vitiligo. BMJ 1990; 300:1468.</a></li><li><a class="nounderline abstract_t">Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking nonsteroidal antiinflammatory drugs. J Pediatr 1994; 125:819.</a></li><li><a class="nounderline abstract_t">Horner ME, Alikhan A, Tintle S, et al. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol 2013; 52:1464.</a></li><li><a class="nounderline abstract_t">Schulenburg-Brand D, Katugampola R, Anstey AV, Badminton MN. The cutaneous porphyrias. Dermatol Clin 2014; 32:369.</a></li><li><a class="nounderline abstract_t">Poh-Fitzpatrick MB, Sosin AE, Bemis J. Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients. J Am Acad Dermatol 1982; 7:100.</a></li><li><a class="nounderline abstract_t">Igawa K, Matsunaga T, Nishioka K. Involvement of UV-irradiation in pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004; 18:216.</a></li><li><a class="nounderline abstract_t">Kano Y, Shimosegawa M, Mizukawa Y, Shiohara T. Pemphigus foliaceus induced by exposure to sunlight. Report of a case and analysis of photochallenge-induced lesions. Dermatology 2000; 201:132.</a></li><li><a class="nounderline abstract_t">Deschamps P, Pedailles S, Michel M, Leroy D. Photo-induction of lesions in a patient with pemphigus erythematosus. Photodermatol 1984; 1:38.</a></li><li><a class="nounderline abstract_t">Reis VM, Toledo RP, Lopez A, et al. UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J Am Acad Dermatol 2000; 42:571.</a></li><li><a class="nounderline abstract_t">Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin 2011; 29:649.</a></li><li><a class="nounderline abstract_t">Massone C, Ambros-Rudolph CM, Di Stefani A, Müllegger RR. Successful outcome of haemodialysis-induced pseudoporphyria after short-term oral N-acetylcysteine and switch to high-flux technique dialysis. Acta Derm Venereol 2006; 86:538.</a></li><li><a class="nounderline abstract_t">Tremblay JF, Veilleux B. Pseudoporphyria associated with hemodialysis treated with N-acetylcysteine. J Am Acad Dermatol 2003; 49:1189.</a></li><li><a class="nounderline abstract_t">Vadoud-Seyedi J, de Dobbeleer G, Simonart T. Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases. Br J Dermatol 2000; 142:580.</a></li><li><a class="nounderline abstract_t">Cooke NS, McKenna K. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine. Clin Exp Dermatol 2007; 32:64.</a></li><li><a class="nounderline abstract_t">Kasuya A, Hashizume H, Hirakawa S, Tokura Y. Haemodialysis-induced pseudoporphyria successfully treated with glutathione. Eur J Dermatol 2012; 22:137.</a></li><li><a class="nounderline abstract_t">Guiotoku MM, Pereira Fde P, Miot HA, Marques ME. Pseudoporphyria induced by dialysis treated with oral N-acetylcysteine. An Bras Dermatol 2011; 86:383.</a></li><li><a class="nounderline abstract_t">Katoulis AC, Ferra D, Toumbis E, et al. Pseudoporphyria associated with nonhemodialyzed renal insufficiency, successfully treated with oral N-acetylcysteine. Case Rep Dermatol Med 2013; 2013:271873.</a></li><li><a class="nounderline abstract_t">Azak A, Yenigün E, Koçak G, et al. Pseudoporphyria in a hemodialysis patient successfully treated with oral glutamine. Hemodial Int 2013; 17:466.</a></li><li><a class="nounderline abstract_t">Pranteda G, Bottoni U, Tayefeh Jafari M, et al. Dialysis-associated pseudoporphyria successfully treated with vitamin D. Report of two cases. G Ital Dermatol Venereol 2015; 150:327.</a></li></ol></div><div id="topicVersionRevision">Topic 13748 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148469" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17266758" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11123786" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213398" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Naproxen-induced pseudoporphyria: a distinctive photodermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118363" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nonsteroidal antiinflammatory drug-induced pseudoporphyria: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25116980" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pseudoporphyria: discussion of etiologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550129" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : [Cutaneous manifestations of chronic hemodialysis. Prospective study of 363 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/643142" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Porphyria cutanea tarda-like syndrome in hemodialyzed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/902828" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : [Detection of pseudo-porphyria cutanea tarda in 100 hemodialyzed patients (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20931673" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14198018" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : PHOTOTOXIC REACTION WITH NALIDIXIC ACID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4733958" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Photosensitivity from nalidixic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4433474" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Photosensitivity from nalidixic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4433474" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Photosensitivity from nalidixic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021136" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pseudoporphyria induced by voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17966183" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pseudoporphyria associated with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17254033" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Voriconazole-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15485539" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pseudoporphyria as a result of voriconazole use: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135074" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Metformin-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20542169" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Imatinib mesylate-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077095" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Imatinib-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24920470" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Imatinib mesylate-induced pseudoporphyria in two children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23451912" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pseudoporphyria induced by imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813651" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sunitinib-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8151484" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7747141" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7777834" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pseudoporphyria due to naproxen. A cluster of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3427818" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Naproxen pseudoporphyria in a patient with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3246085" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Naproxen pseudoporphyria in a patient with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2526917" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Naproxen-induced bullous photodermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954412" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Naproxen-induced pseudoporphyria. A clinical and ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194465" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bullous photosensitivity to naproxen: "pseudoporphyria".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3451093" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pseudoporphyria from nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11128692" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914877" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Nabumetone induced pseudoporphyria in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606389" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Two cases of nabumetone induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583088" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pseudoporphyria and propionic acid non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189244" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pseudoporphyria associated with Relafen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071328" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pseudoporphyria induced by nabumetone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580823" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pseudoporphyria caused by nabumetone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10082597" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pseudoporphyria induced by propionic acid derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10809892" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nabumetone-associated pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990399" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pseudoporphyria induced by mefenamic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/132139" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Porphyria-like cutaneous changes induced by tetracycline hydrochloride photosensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1101760" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Bullous dermatosis of hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1359046" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pseudoporphyria cutanea tarda: two case reports on children receiving peritoneal dialysis and erythropoietin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10401031" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4010846" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cutaneous abnormalities in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1128752" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : On the exudation of plasticizers from PVC haemodialysis tubings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9794565" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3615245" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Porphyrin studies in chronic renal failure patients on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18709330" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pseudoporphyria or porphyria cutanea tarda? Diagnostic and treatment difficulties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2730845" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sunbed-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548659" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Identical twins with sunbed-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1977267" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pseudoporphyria and sunbeds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2748432" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Solarium pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19756434" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [Solarium-induced pseudoporphyria and variegate porphyria as rare differential diagnoses of porphyria cutanea tarda].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31820441" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pseudoporphyria induced by ultraviolet radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1556265" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Histologic and immunofluorescence study of cutaneous porphyrias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12876485" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The sensitivity and specificity of "caterpillar bodies" in the differential diagnosis of subepidermal blistering disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8100120" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Caterpillar bodies: distinctive, basement membrane-containing structures in blisters of porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11357795" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pseudoporphyria: a clinical and biochemical study of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1880250" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2379016" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pseudoporphyria due to dyazide in a patient with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965441" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Increased risk of facial scars in children taking nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24261722" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24891059" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The cutaneous porphyrias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7107989" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009310" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Involvement of UV-irradiation in pemphigus foliaceus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053916" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pemphigus foliaceus induced by exposure to sunlight. Report of a case and analysis of photochallenge-induced lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6531279" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Photo-induction of lesions in a patient with pemphigus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727300" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21925012" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Bullous systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106603" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful outcome of haemodialysis-induced pseudoporphyria after short-term oral N-acetylcysteine and switch to high-flux technique dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639417" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pseudoporphyria associated with hemodialysis treated with N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777273" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of haemodialysis-associated pseudoporphyria with N-acetylcysteine: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305908" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217550" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Haemodialysis-induced pseudoporphyria successfully treated with glutathione.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21603831" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pseudoporphyria induced by dialysis treated with oral N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23662216" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pseudoporphyria associated with nonhemodialyzed renal insufficiency, successfully treated with oral N-acetylcysteine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23461815" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pseudoporphyria in a hemodialysis patient successfully treated with oral glutamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946676" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dialysis-associated pseudoporphyria successfully treated with vitamin D. Report of two cases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
